Aktiesnakken — Februar 2010
-
Genmab står på alle mulige måder så meget bedre end Neuro, at hvis du laver en komparativ analyse af pipeline, cash og markedet så vil du
-
ski..... i bukserne ved neurosearch i 200
-
NUNCA, AND I MEAN NUNCAAAA, MAS BIOTECA
-
fuck.... sad og overvejde alm pantebreve i 22, nu handles den i 33
-
gen skal i 600 hvis neuro er i 200
-
åhhhh
-
jo tak
-
nej, der skal vi nok op i 4670
-
men jeg er klar til at lave de ondeste value investeringer
-
GlaxoSmithKline is charging up to $98,000 for a six-month treatment course of Arzerra, a drug approved in late October for chronic lymphocy
-
which strikes about 15,000 Americans a year. About $60,000 of the cost would be incurred in the first eight weeks, when the drug is given m
-
given more frequently.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind